December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

73.15 -1.08 (-1.45%)
Streaming Delayed Price Updated: 11:01 AM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Analyst Expectations for Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review ↗
 
Via Benzinga
News headline image
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗
The companies are focusing on a small population of ALS patients with a genetic mutation. 
Via Investor's Business Daily
News headline image
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗
 
Via Benzinga
News headline image
Analyst Ratings for Ionis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
Ionis Pharmaceuticals's Earnings Outlook ↗
 
Via Benzinga
News headline image
Analyst Expectations for Ionis Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year ↗
 
Via Benzinga
News headline image
Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile' ↗
 
Via Benzinga
News headline image
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
News headline image
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
From Royalty Pharma plc
Via GlobeNewswire
The Latest Analyst Ratings for Ionis Pharmaceuticals ↗
 
Via Benzinga
Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗
 
Via Benzinga
News headline image
4 Analysts Have This to Say About Ionis Pharmaceuticals ↗
Analysts have provided the following ratings for Ionis Pharmaceuticals (NASDAQ:IONS) within the last quarter: 
Via Benzinga
News headline image
Praxis Precision Outlines Upcoming Plans For Pediatric Epilepsy Programs ↗
 
Via Benzinga
News headline image
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
From Biogen Inc.
Via GlobeNewswire
News headline image
Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗
Neurodegenerative disorders could mean big bucks for some biotechs. 
Via Investor's Business Daily
News headline image
Phillips 66 To Rally 25%? Here Are 5 Other Price Target Changes For Thursday ↗
 
Via Benzinga
News headline image
Ionis Regains Rights To Thrombosis Candidate From Bayer ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗
 
Via Benzinga
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
3 Biotech Stocks to Sell in October ↗
These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market. 
Via InvestorPlace
News headline image
Top-Notch Biohaven Pharmaceutical Stock Trips As ALS Drug Flops In Key Test ↗
Patients didn't show any improvements in a study meant to test multiple drugs. 
Via Investor's Business Daily
News headline image
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
News headline image
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med ↗
 
Via Benzinga
News headline image
There's 'Outsized' Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30% ↗
 
Via Benzinga
News headline image
Analyst Ratings for Ionis Pharmaceuticals ↗
Over the past 3 months, 6 analysts have published their opinion on Ionis Pharmaceuticals (NASDAQ:IONS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary ↗
 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.